Cargando…

Immunotherapies in Huntington's disease and α-Synucleinopathies

Modulation of immune activation using immunotherapy has attracted considerable attention for many years as a potential therapeutic intervention for several inflammation-associated neurodegenerative diseases. However, the efficacy of single-target immunotherapy intervention has shown limited or no ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Fatoba, Oluwaseun, Ohtake, Yosuke, Itokazu, Takahide, Yamashita, Toshihide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052383/
https://www.ncbi.nlm.nih.gov/pubmed/32161599
http://dx.doi.org/10.3389/fimmu.2020.00337
_version_ 1783502860682526720
author Fatoba, Oluwaseun
Ohtake, Yosuke
Itokazu, Takahide
Yamashita, Toshihide
author_facet Fatoba, Oluwaseun
Ohtake, Yosuke
Itokazu, Takahide
Yamashita, Toshihide
author_sort Fatoba, Oluwaseun
collection PubMed
description Modulation of immune activation using immunotherapy has attracted considerable attention for many years as a potential therapeutic intervention for several inflammation-associated neurodegenerative diseases. However, the efficacy of single-target immunotherapy intervention has shown limited or no efficacy in alleviating disease burden and restoring functional capacity. Marked immune system activation and neuroinflammation are important features and prodromal signs in polyQ repeat disorders and α-synucleinopathies. This review describes the current status and future directions of immunotherapies in proteinopathy-induced neurodegeneration with emphasis on preclinical and clinical efficacies of several anti-inflammatory compounds and antibody-based therapies for the treatment of Huntington's disease and α-synucleinopathies. The review concludes with how disease modification and functional restoration could be achieved by using targeted multimodality therapy to target multiple factors.
format Online
Article
Text
id pubmed-7052383
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70523832020-03-11 Immunotherapies in Huntington's disease and α-Synucleinopathies Fatoba, Oluwaseun Ohtake, Yosuke Itokazu, Takahide Yamashita, Toshihide Front Immunol Immunology Modulation of immune activation using immunotherapy has attracted considerable attention for many years as a potential therapeutic intervention for several inflammation-associated neurodegenerative diseases. However, the efficacy of single-target immunotherapy intervention has shown limited or no efficacy in alleviating disease burden and restoring functional capacity. Marked immune system activation and neuroinflammation are important features and prodromal signs in polyQ repeat disorders and α-synucleinopathies. This review describes the current status and future directions of immunotherapies in proteinopathy-induced neurodegeneration with emphasis on preclinical and clinical efficacies of several anti-inflammatory compounds and antibody-based therapies for the treatment of Huntington's disease and α-synucleinopathies. The review concludes with how disease modification and functional restoration could be achieved by using targeted multimodality therapy to target multiple factors. Frontiers Media S.A. 2020-02-25 /pmc/articles/PMC7052383/ /pubmed/32161599 http://dx.doi.org/10.3389/fimmu.2020.00337 Text en Copyright © 2020 Fatoba, Ohtake, Itokazu and Yamashita. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Fatoba, Oluwaseun
Ohtake, Yosuke
Itokazu, Takahide
Yamashita, Toshihide
Immunotherapies in Huntington's disease and α-Synucleinopathies
title Immunotherapies in Huntington's disease and α-Synucleinopathies
title_full Immunotherapies in Huntington's disease and α-Synucleinopathies
title_fullStr Immunotherapies in Huntington's disease and α-Synucleinopathies
title_full_unstemmed Immunotherapies in Huntington's disease and α-Synucleinopathies
title_short Immunotherapies in Huntington's disease and α-Synucleinopathies
title_sort immunotherapies in huntington's disease and α-synucleinopathies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052383/
https://www.ncbi.nlm.nih.gov/pubmed/32161599
http://dx.doi.org/10.3389/fimmu.2020.00337
work_keys_str_mv AT fatobaoluwaseun immunotherapiesinhuntingtonsdiseaseandasynucleinopathies
AT ohtakeyosuke immunotherapiesinhuntingtonsdiseaseandasynucleinopathies
AT itokazutakahide immunotherapiesinhuntingtonsdiseaseandasynucleinopathies
AT yamashitatoshihide immunotherapiesinhuntingtonsdiseaseandasynucleinopathies